Clinical Trial RESULTS
Clinical Trial
RESULTS
Research Sponsor: Ardea Biosciences, Inc.
Drug Studied: RDEA3170
Study Drug Indication: Gout
National Clinical Trial #: NCT02608710
Protocol #: RDEA3170-112
Study Date: November 2015 to January 2016
Short Study Title: A study to determine how RDEA3170 acts in the body
at different doses, over time, and when taken with
or without food
Thank you!
As a clinical study participant, you belong to a large community of participants around the world. You help
researchers answer important health questions and discover new medicines.
Thank you for taking part in the clinical study for the study drug RDEA3170.
RDEA3170 is a study drug being developed to treat gout.
Gout is a type of arthritis or inflammation of the joints that can cause pain and stiffness. Joints are where
two bones meet, like the knee or where the big toe meets the foot. Common symptoms of gout are sudden,
severe attacks of pain, redness, and tender joints.
This study started in November 2015 and ended in January 2016. You and all of the other participants in
this study helped researchers learn how RDEA3170 acts in the body.
Ardea Biosciences, Inc., the sponsor of this study, thanks you and thinks it is important for you to know the
results of your study. An independent non-profit organization called CISCRP prepared this summary of the
study results for you with the assistance of a medical writing organization. We hope it helps you understand
and feel proud of your important role in medical research. If you have questions about the results, please
speak with the doctor or staff at your study site.
1